As expected, we identified the known breast cancer anti-phagocytosis gene B2M (Beta-2-Microglobulin) and the well-known antibody therapeutic target MS4A1 (CD20) in tumor cells 4, 25. This evidence concerns the gene B2M and breast carcinoma.